A panel of exerts discussed key takeaways happening in the field of HER2+ metastatic breast cancer.
ONCOLOGY Vol 40, Issue 4
A panel of exerts discussed key takeaways happening in the field of HR+/HER2– breast cancer.
A panel of exerts discussed key takeaways happening in the field of cutaneous squamous cell carcinoma.
The 2025 ICE-T Symposium highlighted expansion beyond BCMA to additional targets such as GPRC5D and FcRH5.
Julie M. Vose, MD, MBA, discussed how the digital age is impacting oncology care.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Afami-cel in Metastatic Synovial Sarcoma
2
The Moonlight Shift: Dr Joshua Richter on Myeloma, Myths, and the C-Word
3
Current Treatment Landscape of HER2-Positive Metastatic Breast Cancer and Phase 3 Trial Overview
4
How Are Key Lymphoma Data From ASCO and EHA 2026 Shaping Treatment?
5